Information page of INCONCEPTOSTUDIES
Frequently Asked Questions

The ISABELA clinical study program entails two identical designed studies: ISABELA 1 and ISABELA 2. The studies are intended to confirm each other’s results.
The studies consist of an up to 4-week screening period (to see whether patients qualify for participation), a treatment period of at least 52 weeks, and a follow up period of 4 weeks. At least 13 visits to the site are foreseen in these periods. Patient health will be monitored throughout the studies.
ISABELA 1 and 2 will be performed in multiple countries. Current list of planned countries:
- Argentina
- Australia
- Belgium
- Brazil
- Canada
- Chile
- Czech Republic
- Denmark
- France
- Germany
- Greece
- Hungary
- Israel
- Italy
- Japan
- Mexico
- Netherlands
- New Zealand
- Poland
- Peru
- South Africa
- South Korea
- Spain
- Taiwan
- Turkey
- United Kingdom
- United States of America
The studies will include over 200 study sites. In the Study Center Locator you will find active study centers in your region. Please make sure to check back at a later date in case you don’t see any active sites in your region yet. We do not know beforehand exactly when a center will be activated but the Study Center Locator will be updated regularly with most current information.
During the study patients are requested to:
- Take the study medication as instructed by the study doctor
- Attend all scheduled study visits
- Answer questions about their health
- Complete lung function tests
- Provide urine and blood samples at study visits
- Follow all instructions from the study staff